I suspect this problem will self-correct. It's not that we've run out of choices: it's partially that pharmaceutical companies had the narrow view that developing new antibiotic drugs is less profitable than developing drugs for chronic illness (e.g., to control cholesterol); once catastrophe hits due to bacteria being resistant to all current drugs, it will be extremely profitable to work on this class of drugs again. Take a look at this interview with Dr. John Rex M.D., (V.P., Clinical Research, AstraZeneca) [1]<p>"Dr. JOHN REX: If you need an antibiotic, you need it only briefly. Indeed, that’s the— that’s the correct way to use an antibiotic. You use it only briefly.<p>And from an economic standpoint of a developer, that means you’re not— you’re not getting the return on the investment you’ve made because you’ve spent between $600 million and a billion dollars to bring that new antibiotic to market."<p>[1] <a href="http://www.pbs.org/wgbh/pages/frontline/health-science-technology/hunting-the-nightmare-bacteria/transcript-51/" rel="nofollow">http://www.pbs.org/wgbh/pages/frontline/health-science-techn...</a>